Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis

NCT00034853 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00034853
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00034853 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2000
Completion date
Not reported
Enrollment
180 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, juvenile rheumatoid